Mk 3222

ALL
News
Opinion
Photos
Videos

Jump to

Analysts bet psoriasis drug to aid Sun Pharma's US kitty

However, higher competition in Taro's products, re-inspection of Halol resulting in more observations which could delay earnings recovery from the Halol plant may pose threat to the company.
Sun's psoriasis trial drug won't hit mkt before FY19: Analyst

Sun Pharma has completed a 12 weeks trial of its psoriasis drug, MK 3222, but needs 52-124 weeks data to apply for a license with the US FDA, says Surajit Pal, pharma analyst at Prabhudas Lilladher.

Advisory Alert: It has come to our attention that certain individuals are representing themselves as affiliates of Moneycontrol and soliciting funds on the false promise of assured returns on their investments. We wish to reiterate that Moneycontrol does not solicit funds from investors and neither does it promise any assured returns. In case you are approached by anyone making such claims, please write to us at grievanceofficer@nw18.com or call on 02268882347

Mk 3222

Analysts bet psoriasis drug to aid Sun Pharma's US kitty

Sun's psoriasis trial drug won't hit mkt before FY19: Analyst